Nestle’s Acquisition of Zenpep

Debevoise & Plimpton LLP advised Allergan plc on the deal. Mayer Brown acted as legal advisor to Nestlé on the deal.

Nestlé entered into an agreement to acquire Zenpep (pancrelipase)

Nestlé (Swiss: NESN) will acquire and take full operational ownership of Zenpep upon closing the transaction with customary transition support from Allergan. Zenpep is a treatment, which is available in the United States, for exocrine pancreatic insufficiency due to cystic fibrosis and other conditions. Nestlé also will be acquiring Viokace, another pancreatic enzyme preparation, as part of the same transaction.

ZENPEP® (pancrelipase) is a prescription medication for people who cannot digest food normally because their pancreas does not make enough enzymes.  ZENPEP may help your body use fats, proteins, and sugars from food. ZENPEP contains a mixture of digestive enzymes (lipases, proteases, and amylases) from pig pancreas. In clinical studies, individuals with exocrine pancreatic insufficiency associated with cystic fibrosis absorbed more fat from foods than those treated with a placebo.

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.

The Debevoise team is led by M&A partner Andrew Bab (Picture) and includes M&A partners Jennifer Chu, Sue Meng and Thomas Schürrle, counsel Molly Stockley and associates William Barlow, Lauren Beasley, David Becker, Zhiyan Cao, Benjamin Collins-Wood, Michelle Guo, James Harrington, Gabriel Pollack and Friedrich Popp, tax partner Gary Friedman and associate Samuel Krawiecz, benefits partner Jonathan Lewis, intellectual property partner Henry Lebowitz and associate Jose Lamarque and FDA regulatory partner Paul Rubin and associate Melissa Runsten.

The Mayer Brown team included: Corporate & Securities – partners David Carpenter, John Boelter and Reb Wheeler and associates Omar El-Khattabi (DC), Karen Chong, Lily Song, Michael Russo and Daniela Abadi (all NY); IP – partners Joseph Mahoney (Charlotte) and Richard Assmus (Chicago) and associates Scott McMurry, Lana Khoury and Ryan Babcock (all NY); Tax Transactions & Consulting – partner Remmelt Reigersman (NorCal) and associate George Haines (Chicago); and Litigation & Dispute Resolution – partners Elizabeth Mann (LA), Mark Ryan and Adam Hudes and counsel Meytal McCoy (all DC).

Involved fees earner: Andrew Bab – Debevoise & Plimpton; William Barlow – Debevoise & Plimpton; Lauren Beasley – Debevoise & Plimpton; David Becker – Debevoise & Plimpton; Zhiyan Cao – Debevoise & Plimpton; Jennifer Chu – Debevoise & Plimpton; Benjamin Collins-Wood – Debevoise & Plimpton; Gary Friedman – Debevoise & Plimpton; Michelle Guo – Debevoise & Plimpton; James Harrington – Debevoise & Plimpton; Samuel Krawiecz – Debevoise & Plimpton; Jose Angel Lamarque III – Debevoise & Plimpton; Henry Lebowitz – Debevoise & Plimpton; Jonathan Lewis – Debevoise & Plimpton; Sue Meng – Debevoise & Plimpton; Gabriel Pollack – Debevoise & Plimpton; Friedrich Popp – Debevoise & Plimpton; Paul Rubin – Debevoise & Plimpton; Melissa Runsten – Debevoise & Plimpton; Thomas Schürrle – Debevoise & Plimpton; Molly Stockley – Debevoise & Plimpton; Daniela Abadi – Mayer Brown; Richard Assmus – Mayer Brown; Ryan Babcock – Mayer Brown; John Boelter – Mayer Brown; David Carpenter – Mayer Brown; Karen Chong – Mayer Brown; Omar El-Khattabi – Mayer Brown; George Haines – Mayer Brown; Adam Hudes – Mayer Brown; Lana Khoury – Mayer Brown; Joseph Mahoney – Mayer Brown; Elizabeth Mann – Mayer Brown; Meytal McCoy – Mayer Brown; Scott McMurry – Mayer Brown; Remmelt Reigersman – Mayer Brown; Michael Russo – Mayer Brown; Mark Ryan – Mayer Brown; Lily Song – Mayer Brown; Reb Wheeler – Mayer Brown;

Law Firms: Debevoise & Plimpton; Mayer Brown;

Clients: Allergan; Nestlé Health Science;

Author: Ambrogio Visconti